Fig. 2

Inactivation of P38 MAPK and reduction of MAP2K3 could reduce CVB3 replication. Hela cells were pretreated with P38 inhibitor SB203580 or MAP2K3 specific siRNA (MAP2K3-siRNA as shown in the figure) and were then infected with CVB3 at MOI = 1. DMSO and siRNA has no targets (siRNA-con as shown in the figure) were used as control. a Western bolt was conducted to detect P-P38 and downstream P-HSP27 in the presence of SB203580 7 h post CVB3 infection, DMSO was loaded as control group. b CVB3 replication in the supernatants of SB203580 treated cells at indicated time point were detected. c Western bolt was conducted to detect MAP2K3, P-P38 and downstream P-HSP27 expression in MAP2K3 specific siRNA treated cells 7 h post CVB3 infection. siRNA has non targets to the human genome was tested as a control. Shown were representative results from 3 independent tests. d CVB3 replication in the supernatants of siRNA-MAP2K3 treated cells were detected at indicated time point. Virus titer values represent the means and standard deviations of three independent experiments, (*p < 0.05)